Last Updated: November 16, 2026

Investigational Drug Information for HMPL-689

« Back to Dashboard


What is the drug development status for HMPL-689?

HMPL-689 is an investigational drug.

There have been 6 clinical trials for HMPL-689. The most recent clinical trial was a Phase 1 trial, which was initiated on February 1st 2023.

The most common disease conditions in clinical trials are Lymphoma, Lymphoma, Follicular, and Lymphoma, B-Cell, Marginal Zone. The leading clinical trial sponsors are Hutchison Medipharma Limited, Hutchmed, and [disabled in preview].

There are twenty US patents protecting this investigational drug and one hundred and sixty-five international patents.

Recent Clinical Trials for HMPL-689
TitleSponsorPhase
A Study of Tazemetostat in Combination With HMPL-689 in Patients With Relapsed/Refractory LymphomaHutchmedPhase 2
HMPL-689 Drug Interaction Study With CYP3A Inhibitor/CYP2C9 Inhibitor/CYP3A Inducer/PPIHutchmedPhase 1
Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular LymphomaHutchison Medipharma LimitedPhase 2

See all HMPL-689 clinical trials

Clinical Trial Summary for HMPL-689

Top disease conditions for HMPL-689
Top clinical trial sponsors for HMPL-689

See all HMPL-689 clinical trials

US Patents for HMPL-689

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
HMPL-689 ⤷  Start Trial Imidazopyridazine compounds and their use Hutchmed Ltd ⤷  Start Trial
HMPL-689 ⤷  Start Trial Crystalline forms of tenofovir alafenamide GILEAD SCIENCES, INC. (Foster City, CA) ⤷  Start Trial
HMPL-689 ⤷  Start Trial Substituted pyrrolizine compounds and uses thereof GILEAD SCIENCES, INC. (Foster City, CA) ⤷  Start Trial
HMPL-689 ⤷  Start Trial Imidazopyridazine compounds and their use Hutchmed Ltd ⤷  Start Trial
HMPL-689 ⤷  Start Trial PD-1/PD-L1 inhibitors Gilead Sciences, Inc. (Foster City, CA) ⤷  Start Trial
HMPL-689 ⤷  Start Trial PD-1/PD-L1 inhibitors Gilead Sciences, Inc. (Foster City, CA) ⤷  Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for HMPL-689

Drugname Country Document Number Estimated Expiration Related US Patent
HMPL-689 Argentina AR110768 2037-01-31 ⤷  Start Trial
HMPL-689 Australia AU2018216738 2037-01-31 ⤷  Start Trial
HMPL-689 Australia AU2021200857 2037-01-31 ⤷  Start Trial
HMPL-689 Australia AU2022283687 2037-01-31 ⤷  Start Trial
HMPL-689 Canada CA3049028 2037-01-31 ⤷  Start Trial
HMPL-689 Canada CA3168042 2037-01-31 ⤷  Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.